Travere Therapeutics Inc Aktie News

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on December 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 20,300 shares of its common stock. These inducement RSUs are subject to the terms of Travere...

The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday.  The sector has bounced back since. However, small biotech stocks have been on a huge run since mid-September, due primarily to a notable uptick in M&A activity across the industry. Numerous small and midcap biotech/biopharma stocks have been purchased for signif...

Travere Therapeutics has surged ~107% since my last 'Buy' rating, driven by FILSPARI's strong performance and approvals. TVTX's market cap has more than doubled in six months, reflecting confidence in FILSPARI's role in treating primary IgAN. Recent FDA REMS modifications for FILSPARI have eased monitoring requirements, improving its commercial prospects and patient accessibility.

New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares of Travere Therapeutics valued at $160.7 million.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on November 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 25,700 shares of its common stock. These inducement RSUs are subject to the terms of Traver...

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced new data from the Phase 3 DUPLEX Study demonstrating that patients with focal segmental glomerulosclerosis (FSGS) treated with FILSPARI® (sparsentan) were significantly more likely to reach proteinuria levels below 0.7 g/g compared to those receiving the maximum labeled dose of irbesartan, and achie...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: Guggenheim's 2nd Annual Healthcare Innovation Conference Presenting on Tuesday, November 11, 2025, at 9:00 a.m. ET Stifel 2025 Healthcare Conference Wednesday, November 12, 2025 TD Cowen Immunology & Inflammation Summit Pr...

Travere Therapeutics stock popped Friday — poising itself to top a buy zone — on another sales beat from its linchpin drug, Filspari.